Increases in the expression of prostaglandin E2 (PGE2) are widely known to be involved in aberrant growth in the early stage of colon cancer development. We herein demonstrated that the novel indole compound MW-03 reduced PGE2-induced cAMP formation by catalization to an inactive metabolite by inducing 15-hydroxyprostaglandin dehydrogenase through the activation of peroxisome proliferator-activated receptor-γ. MW-03 also inhibited colon cancer cell growth by arresting the cell cycle at the S phase. Although the target of MW-03 for cell cycle inhibition has not yet been identified, these dual anti-cancer effects of MW-03 itself and/or its leading compound(s) on colon cancer cells may reduce colon cancer development and, thus, have potential as a novel treatment for the early stage of this disease.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/626040 |
| Date | 10 1900 |
| Creators | Seira, Naofumi, Yanagisawa, Naoki, Suganami, Akiko, Honda, Takuya, Wasai, Makiko, Regan, John W, Fukushima, Keijo, Yamaguchi, Naoto, Tamura, Yutaka, Arai, Takayoshi, Murayama, Toshihiko, Fujino, Hiromichi |
| Contributors | Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol |
| Publisher | PHARMACEUTICAL SOC JAPAN |
| Source Sets | University of Arizona |
| Language | English |
| Detected Language | English |
| Type | Article |
| Rights | © 2017 The Pharmaceutical Society of Japan |
| Relation | https://www.jstage.jst.go.jp/article/bpb/40/10/40_b17-00458/_article |
Page generated in 0.0019 seconds